Treatment of lobar atelectasis with bronchoscopically administered recombinant human deoxyribonuclease in cystic fibrosis?

Aisling McLaughlin, Emmet McGrath, R Barry, JJ Egan, CG Gallagher

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

INTRODUCTION Recombinant human deoxyribonuclease (rhDNase) reduces sputum viscosity and improves pulmonary function in cystic fibrosis (CF). OBJECTIVE The objective of this study was to describe our experience in which rhDNase (Pulmozyme; Roche, Basel, Switzerland) was administered by bronchoscopic instillation into atelectatic lobes in five adults with CF. CONCLUSION We found this method successful in treating lobar atelectasis, which was resistant to conventional therapy with antibiotics and physiotherapy. In all but one of the cases we described, administration of DNase in this manner resulted in a radiographic and clinical improvement of the atelectasis. We recommend that respiratory physicians consider this as a second line treatment in the management of atelectasis.
Original languageEnglish
Pages (from-to)123-126
Number of pages4
JournalThe Clinical Respiratory Journal
Volume2
Issue number2
DOIs
Publication statusPublished - 1 Jan 2008

Fingerprint

Dive into the research topics of 'Treatment of lobar atelectasis with bronchoscopically administered recombinant human deoxyribonuclease in cystic fibrosis?'. Together they form a unique fingerprint.

Cite this